non-covalent, pan-mutant selective EGFR inhibitors (Genentech)

N/A

Report date: 2025/01/26 16:34:23
NME

Base Information

Drug Namenon-covalent, pan-mutant selective EGFR inhibitors (Genentech)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReceptor tyrosine-protein kinase erbB antagonists
TargetsEpidermal growth factor receptor erbB1Receptor tyrosine-protein kinase erbB
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesGenentech Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A